methylation reached nadir at best response and gradually increased thereafter. An elevation of mutation AF or the emergence of new mutation(s) (molecular PD) was observed in 4 patients prior to PD assessed by imaging. In all patients, an elevation of DNA methylation was observed prior to PD assessed by imaging; among them, 3 had changes in DNA methylation prior to molecular PD, suggesting DNA methylation may be a more sensitive biomarker. Conclusion: Collectively, our study demonstrates DNA methylation, continuously increasing from the nadir (best response), can be utilized as a biomarker for treatment monitoring.
P2.04-01 Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.
G. Cruz-Rico, 1 X. Popa Navarro, 1 A. Avilés-Salas, 1 K.Y. Flores-Vélez, 1 A. Cardona, 2 L. Ramírez-Tirado, 1 E. Vergara, 1 F. Barron, 3 L.A. Cabrera-Miranda, 1 O. Arrieta 3 1 Instituto Nacional de Cancerología, México/MX, 2 Clinical and Translational Oncology Group, Foundation for Clinical and Applied Cancer Research -Ficmac, Bogotá/ CO, 3 National Cancer Institute, Mexico City/MX Background: The analysis by immunohistochemistry (IHC) of the programmed cell death-ligand 1 (PD-L1) protein expression is the most extensively explored biomarker for response to immunotherapy in non-small cell lung cancer (NSCLC). However, there are differences concerning diverse IHC assays and cut-off criteria: Pembrolizumab with the 22C3 assay with cut-off ranges of >1%, 1-49% and >50%; and Nivolumab with the 28-8 assay and ranges of <1%, 1-5%, 5 -10% and >10%. Furthermore, there is lack of information regarding the association between the histological subtype of adenocarcinoma and PD-L1 expression. In this work, we assessed the frequency of PD-L1 expression according with to histological subtype of adenocarcinoma. Method: PD-L1 expression was assessed using the PD-L1 IHC 22C3 pharmDx immunohistochemistry assay (Dako North America, Inc.). We correlated histological subtype of adenocarcinoma with the frequency and intensity of PD-L1 expression, smoking history, EGFR and ALK status. Result: Tissue samples from one hundred and sixty-two were analyzed, of which 33 (20.4%) were excluded due to insufficient material for PD-L1asessment. Among them, 106 patients (71,55%) were female, the median age was 63 years (range 31-86 years), 69 (53.5%) were never-smokers with no exposition to wood smoke or asbestos (79,61.2% and 117, 90.7% respectively) . Among the 129 adenocarcinomas, 31.0% were acinar histological subtype; 27.1% solid, 17.1% papillary, 3.9% lepidic, 1.6% micropapillary and 54.3% had a moderated tumor differentiation grade. According to PD-L1 score, 49 (38%) of the patients were classified as negative (PD-L1<1%), 71(55%) as poor PD-L1 expression (1 -49%), and 9 (7%) as strong PD-L1 expression (50%). According to the IASLC/ATS adenocarcinoma histological subtype was associated with PD-L1 expression (p¼0.003). Solid and acinar adenocarcinomas were more likely to present strong PD-L1 expression (55.6% and 33.3%, respectively) compared to lepidic, papillary, micropapillary and unspecified tumors, which presented a strong PD-L1 expression in up to 11.1%. Median PFS to first line therapy was 10.3 (95% CI: 6.1e14.5) months. Tobacco exposure was the only factor independently associated with an increase in the hazard of progression to first line therapy (either CT or TKI) from any cause among NSCLC patients (HR, 95% CI: 1.56-12.1). The median OS was 41.9 (95% CI: 10.9e72.9) months. Median OS differences were not found among PD-L1 (negative vs. positive: 60.6 vs. 31.3 months, p¼0.685). Conclusion: Patients with adenocarcinoma tumors, solid histological subtype and poor differentiation grade can be more benefited with a PD-1 based immunotherapy. PD-L1 score can be a predictor factor for the response to first line chemotherapy. Keywords: Programmed-death receptor ligand 1, Immunotherapy, NSCLC P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab
Background: Immunotherapy represents a dramatic change in the treatment of non small cell lung cancer (NSCLC), but nowadays prognostic and predictive factors of response to immune checkpoint inhibitors (ICIs) are still under debate. It has been observed that circulating biomarkers might have a prognostic role in lung cancer. The aim of this study was to determine whether circulating tumor cells (CTCs) as well as circulating free DNA (cfDNA) might predict the outcome of patients with advanced NSCLC treated with Nivolumab. Method: From May 2015 to April 2017 89 NSCLC patients were treated with Nivolumab as a second or further line of therapy. All patients underwent blood sample collection before the start of treatment (baseline) and after 4 and 7 cycles of Nivolumab to evaluate both biomarkers. CTCs were isolated from 3mL of blood by the filtration-based device ScreenCell Cyto (ScreenCell) according to manufacturer's protocol. cfDNA was extracted from plasma using the QIAamp DNA Blood Mini Kit (Qiagen) and quantified (ng/mL) by qPCR method, using hTERT single copy gene. The median baseline CTC number and cfDNA content were used as cut-off values to discriminate patients with different outcomes. An univariate analysis was done to evaluate the overall survival (OS) in the study population based on CTC and cfDNA using the Kaplan Meyer method. Result: The median CTC number and cfDNA at baseline were 2/3mL and 836.5 ng/mL, respectively. Median OS was 8.8 and 6.2 months for patients with baseline CTC 2 and >2, respectively (HR 1.53, 95% CI 0.96-2.42; p¼0.072). Similarly, patients with high level of cfDNA > 836.5 ng/ml showed a worse OS as compared with those having lower cfDNA: 5.1 vs 9.4 months (HR 1.63, 95% CI 1.02-2-59; p¼0.040). Conclusion: A statistically significant advantage in terms of OS was observed in the group of patients with baseline cfDNA below the median value. Similarly, a longer survival, although of borderline significance, was observed in the group of patients with baseline CTC 2. Longitudinal change evaluations of both circulating biomarkers compared to radiological tumor size are currently ongoing. Keywords: circulating free DNA, Circulating tumor cells, Immunotherapy P2.04-03 NF-kB and HIF-1a Play Important Roles in Regulating PD-L1 Expression by EGFR or KRAS Mutants in Non-Small Cell Lung Cancer Cells R. Guo, 1 J. Wang, 1 Y. Li, 2 H. Bai 1 1 Cancer Hospital Chinese Academy of Medical Sciences, Beijing/CN, 2 Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing/CN Background: Programmed death ligand 1 (PD-L1) is expressed in various human tumors and is of critical importance for the immune escape of tumor cells. Some driver gene mutations including EGFR and KRAS have been reported to be involved in PD-L1 expression regulation. However, the potential role and precise mechanism of EGFR and KRAS mutants in PD-L1 expression regulation in non-small cell lung cancer (NSCLC) remain obscure. Method: The expression levels of PD-L1 and key molecules of EGFR and KRAS signaling pathways were examined in 11 NSCLC cells with wild-type or mutant EGFR and KRAS genes. Additionally, ectopic expression or depletion of EGFR or KRAS mutants and pharmacological inhibitors of MEK/ERK, PI3K/AKT, IkBa, and HIF-1a were employed to elucidate the effects of activation or inhibition of EGFR or KRAS pathway on PD-L1 expression regulation in NSCLC cells. The effects of pathway inhibitors on tumorigenesis and PD-L1 expression of EGFR or KRAS-mutated NSCLC cells were also examined using xenograft mouse model, Furthermore, the correlations between EGFR and KRAS status and protein levels of HIF-1a and PD-L1 were analyzed in 97 NSCLC tissues. Result: Examination of the EGFR and KRAS signaling cascades in NSCLC cells revealed an apparent association of PD-L1 overexpression with activation of MEK/ERK and PI3K/AKT pathways, especially with increased protein levels of p-IkBa and HIF-1a. Notably, ectopic expression or depletion of EGFR or KRAS mutants and administration of EGFR or KRAS pathway inhibitors showed important interplay and cooperation between NF-kB and HIF-1a in PD-L1 expression regulation in NSCLC cells. Furthermore, administration of EGFR or KRAS pathway inhibitors significantly inhibited xenograft tumor growth and PD-L1 expression of NSCLC cells in nude mice. Moreover, NSCLC tissues with positive HIF-1a staining presented significantly increased positive rate of PD-L1 expression compared with tissues scored HIF-1a negative (49.1% vs. 20.5%, P ¼ 0.003). NSCLC tissues with EGFR or KRAS mutants showed obviously elevated expression levels of HIF-1a and PD-L1 compared with tissues carrying wild-type EGFR and KRAS genes (68.4% vs. 43.4%, P ¼ 0.018 and 50.0% vs. 28.3%, P ¼ 0.035, respectively). Conclusion: Taken together, both EGFR and KRAS mutants were identified to regulate PD-L1 expression via signaling effectors, NF-kB and HIF-1a, suggesting the correlation between driver gene mutations and tumor immune escape in NSCLC. Keywords: EGFR, KRAS, PD-L1, NF-kB, HIF-1a, NSCLC.
P2.04-04 Expression of Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral CD4 + T Cell, CD8 + T Cell and FOXP3 + T Cell in Lung Cancer Y. Jin, 1 H. Shimada, 1 S. Yamauchi, 1 N. Inase, 1 O. Matsubara 2 1 Respiratory Medicine, Hiratsuka Kyousai Hospital, Hiratsuka, Kanagawa/JP, 2 Pathology, Hiratsuka Kyosai Hospital, Hiratsuka Kanagawa/JP Background: Overexpression of PD-1 and PD-L1 induces immune evasion by cancer cells. Blockade of this immune checkpoint could reverse the tumor immune system and activate the anti-cancer response. Nivolumab and pembrolizumab, anti-PD-1 antibodies, were recently approved for the treatment of advanced NSCLC. A PD-L1 positive expression status by immunohistochemistry (IHC) has been associated with a favorable response. However responses to these drugs are limited, with the objective response rate ranging between 20%-30%. These results suggest that individual tumor microenvironments vary according to the immune evasion process of each cancer tissue. Consequently, the introduction of biomarkers, which predict the responders to the immune checkpoint blockades are necessary in clinical practice. FOXP3 + CD4 + regulatory T cells recognizing tumorspecific shared antigens maintain the immunological self-tolerance and suppress the activation of T cells in cancer tissue. Moreover, anti-CTLA-4 monoclonal antibody therapy reduces FOXP3 + CD4 + expression in cancer tissue. However, the precise conditions and diagnostic value of these immunological factors remain uncertain and specific biomarkers predictive of response have not yet been identified. Method: PD-L1, CD4, CD8 and FOXP3 expression in tumor cells and tumor infiltrating lymphocytes (TILs) were examined by IHC in 45 cases (including 32 cases of adenocarcinoma and 13 cases of squamous cell carcinoma) with advanced lung cancer treated with nivolumab or pembrolizumab. Histologic subtypes, tumor stage and other clinicopathologic conditions were compared with the level of their expression. Result: Expression of PD-L1 expression in tumor cells was detected in 75.6% of the cases. The objective response rate was 46.7%, and it was significantly correlated PD-L1 positivity with CD8 TILs (p<0.0001). Eleven cases having driver gene mutations did not show a tendency towards favorable response. Cases with PD-L1 overexpression showed consistently dense CD8 + TILs, even in subgroup analyses according to histological subtype, stage, age and smoking status. In cancer-associated stroma, CD4 + cells and FOXP3 + positive cells were detected, and cases with PD-L1-, low CD8 + , and FOXP3 + status were also detected. Conclusion: Overexpression of PD-L1 with CD8 + TILs was associated with a favorable response to treatment with nivolumab and pembrolizumab. In contrast, PD-L1-with low CD8 + TILs and FOXP3 + TILs was not associated with favorable response. Therefore, assessment of PD-L1, CD8 + TILs and FOXP3 + TILs by IHC may be valuable for predicting response to treatment with nivolumab and pembrolizumab. PD-L1-and CD8 + TILs and FOXP3 + TILs may be indicative of a combination with other therapeutic agents. Investigation of novel combinations of immunotherapy according to individual tumor microenvironments is warranted. Keywords: PD-L1, CD8+ T cell, FOXP3+ T cell
